OXFORD PHARMAGENESIS LIMITED
Get an alert when OXFORD PHARMAGENESIS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-07-31 (in 2mo)
Last filed for 2024-10-31
Confirmation statement due
2027-01-21 (in 8mo)
Last made up 2026-01-07
Watchouts
None on the register
Cash
£6M
-28.9% vs 2023
Net assets
£19M
-26.2% vs 2023
Employees
416
-2.6% vs 2023
Profit before tax
£7M
-3.3% vs 2023
Net assets
2-year trend · vs Consumer Discretionary median
Accounts
2-year trend · latest reflected 2024-10-31
| Metric | Trend | 2023-10-31 | 2024-10-31 |
|---|---|---|---|
| Turnover | £46,258,294 | £44,188,955 | |
| Operating profit | £7,107,685 | £6,783,701 | |
| Profit before tax | £7,476,574 | £7,231,749 | |
| Net profit | £5,748,009 | £5,437,642 | |
| Cash | £7,914,679 | £5,627,220 | |
| Total assets less current liabilities | £26,953,260 | £19,953,010 | |
| Net assets | £26,432,749 | £19,495,291 | |
| Equity | £26,432,749 | £19,495,291 | |
| Average employees | 427 | 416 | |
| Wages | £24,703,326 | £23,852,209 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-10-31 | 2024-10-31 |
|---|---|---|---|
| Operating margin | 15.4% | 15.4% | |
| Net margin | 12.4% | 12.3% | |
| Return on capital employed | 26.4% | 34.0% | |
| Current ratio | 3.94x | 2.60x | |
| Interest cover | 142.22x | 87.33x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Shaw Gibbs (Audit) Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future, thus they continue to adopt the going concern basis of accounting in preparing these financial statements.”
Group structure
- OXFORD PHARMAGENESIS LIMITED · parent
- Oxford PharmaGenesis AG 100%
- Oxford PharmaGenesis Inc 100%
- Oxford PharmaGenesis Pty Ltd 100%
Significant events
- “During the year, we established an AI Task Force to explore ways in which our delivery teams can develop and utilities AI to better serve our clients.”
- “Proud to be bearers of the King's Award for Enterprise, the most prestigious business award in the country, which recognises the company's outstanding achievement in international trade.”
- “continued commitment to support a funded DPhil studentship in Translational Health Sciences in collaboration with Green Templeton College at the University of Oxford.”
- “During the year the company made charitable donations of £39,126 (2023: £70,641).”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
7 active · 7 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| TUSTIAN, James Edward | Secretary | 2022-05-31 | — | — |
| FARROW, Paul James | Director | 2022-11-01 | Oct 1978 | British |
| HILL, Catherine Elizabeth | Director | 2022-11-01 | Feb 1979 | British |
| RAINS, Christopher Philip | Director | 2024-06-01 | Aug 1966 | British |
| TUSTIAN, James Edward | Director | 2022-11-01 | Dec 1977 | British |
| WHITE, Richard, Dr | Director | 2011-07-20 | Jan 1975 | British |
| WINCHESTER, Christopher Charles, Dr | Director | 2011-07-20 | Jul 1971 | British |
Show 7 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| SHELTON, Julia Clare | Secretary | 1998-01-06 | 2013-07-10 |
| SWIFT INCORPORATIONS LIMITED | Corporate Nominee Secretary | 1998-01-06 | 1998-01-06 |
| FALCONE, Brian | Director | 2022-11-01 | 2023-06-01 |
| FROST, Sharon Michele | Director | 2022-11-01 | 2024-11-29 |
| SHELTON, Graham Anthony Brian, Dr | Director | 1998-01-06 | 2024-10-24 |
| SHELTON, Julia Clare | Director | 1998-01-06 | 2013-07-10 |
| THOMAS, Christopher John | Director | 2011-07-20 | 2018-12-04 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Oxford Pharmagenesis Holdings Limited | Corporate entity | Shares 75–100% | 2016-04-06 | Active |
Filing timeline
Last 20 of 127 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-01-08 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-05-09 | AA | accounts | Accounts with accounts type full | |
| 2025-01-08 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-12-16 | TM01 | officers | Termination director company with name termination date | |
| 2024-11-07 | TM01 | officers | Termination director company with name termination date | |
| 2024-06-14 | AP01 | officers | Appoint person director company with name date | |
| 2024-05-14 | AA | accounts | Accounts with accounts type full | |
| 2024-01-12 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-06-09 | TM01 | officers | Termination director company with name termination date | |
| 2023-05-03 | AA | accounts | Accounts with accounts type full | |
| 2023-03-13 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2023-03-13 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2023-03-13 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2023-03-13 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2023-01-19 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-11-14 | AP01 | officers | Appoint person director company with name date | |
| 2022-11-14 | AP01 | officers | Appoint person director company with name date | |
| 2022-11-14 | AP01 | officers | Appoint person director company with name date | |
| 2022-11-14 | AP01 | officers | Appoint person director company with name date | |
| 2022-11-14 | AP01 | officers | Appoint person director company with name date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-10-31 vs 2023-10-31
-
Turnover
-4.5%
£46,258,294 £44,188,955
-
Cash
-28.9%
£7,914,679 £5,627,220
-
Net assets
-26.2%
£26,432,749 £19,495,291
-
Employees
-2.6%
427 416
-
Operating profit
-4.6%
£7,107,685 £6,783,701
-
Profit before tax
-3.3%
£7,476,574 £7,231,749
-
Wages
-3.4%
£24,703,326 £23,852,209
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers